• Profile
Close

Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study)

Journal of Diabetes Investigation Jun 23, 2019

Miura H, et al. - Researchers investigated the impacts of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, ipragliflozin, including those on appetite-regulating hormones, in individuals with suboptimally controlled type 2 diabetes in order to explore whether SGLT-2 inhibitors could increase appetite by affecting related hormones. The study sample consisted of 96 patients with a body mass index of ≥22 kg/m2 who were treated with ipragliflozin (50 mg/day) for 16 weeks. After treatment for 16 weeks, both glycated hemoglobin level and body weight were significantly reduced. The results obtained from the present prospective, multicenter, open-label study indicate that ipragliflozin improved glycemic control and reduced body weight, but also reduced serum leptin levels and may have increased appetite as a result.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay